EPHX1 and pancreatic neoplasm: By preventing TRIM21‐mediated ubiquitination and subsequent degradation of EPHX1, Bezafibrate sensitizes pancreatic cancer cells to gemcitabine, offering a novel and promising therapeutic strategy.